Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.

Abstract

A new anticopper drug, tetrathiomolybdate (TM), developed for Wilson's disease, is a very promising antiangiogenic agent. Copper levels lowered into an antiangiogenic window by TM have shown efficacy against cancer in a variety of animal models as well as in patients. The only significant toxicity so far results from overtreatment and excessive bone marrow… (More)

Topics

Cite this paper

@article{Brewer2002CancerTW, title={Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.}, author={George J. Brewer and Sof{\'i}a D. Merajver}, journal={Integrative cancer therapies}, year={2002}, volume={1 4}, pages={327-37} }